SVEGLIATI BARONI, Gianluca
 Distribuzione geografica
Continente #
NA - Nord America 6.414
EU - Europa 3.438
AS - Asia 1.558
SA - Sud America 199
AF - Africa 93
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 2
Totale 11.710
Nazione #
US - Stati Uniti d'America 6.372
UA - Ucraina 610
IT - Italia 507
RU - Federazione Russa 451
SG - Singapore 438
HK - Hong Kong 409
IE - Irlanda 403
CN - Cina 399
DE - Germania 378
SE - Svezia 378
DK - Danimarca 199
BR - Brasile 185
FI - Finlandia 172
TR - Turchia 148
GB - Regno Unito 136
FR - Francia 109
KR - Corea 97
MA - Marocco 44
CI - Costa d'Avorio 39
CA - Canada 36
IN - India 25
BE - Belgio 22
PL - Polonia 21
AT - Austria 14
NL - Olanda 12
UZ - Uzbekistan 7
EU - Europa 6
MX - Messico 5
PK - Pakistan 5
EC - Ecuador 4
LU - Lussemburgo 4
RO - Romania 4
RS - Serbia 4
TW - Taiwan 4
VN - Vietnam 4
CH - Svizzera 3
EG - Egitto 3
IQ - Iraq 3
JP - Giappone 3
LT - Lituania 3
PY - Paraguay 3
ZA - Sudafrica 3
AR - Argentina 2
AU - Australia 2
AZ - Azerbaigian 2
ES - Italia 2
IR - Iran 2
KE - Kenya 2
PE - Perù 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BD - Bangladesh 1
BG - Bulgaria 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
HN - Honduras 1
HR - Croazia 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
ME - Montenegro 1
MM - Myanmar 1
MY - Malesia 1
NP - Nepal 1
PT - Portogallo 1
SI - Slovenia 1
TH - Thailandia 1
TN - Tunisia 1
VE - Venezuela 1
Totale 11.710
Città #
Chandler 778
Jacksonville 651
Fairfield 593
Des Moines 459
Hong Kong 409
Ashburn 400
Dublin 400
Boardman 381
Wilmington 283
Woodbridge 268
Houston 243
Singapore 214
Seattle 204
Cambridge 190
New York 188
Centro 172
Lawrence 152
Princeton 152
San Mateo 144
Ann Arbor 142
Munich 98
San Diego 88
Moscow 84
The Dalles 75
Guangzhou 71
Helsinki 70
Beijing 52
Turin 48
Los Angeles 41
Abidjan 39
London 36
Washington 33
Wuhan 33
Ottawa 25
Ancona 22
Shanghai 22
Norwalk 21
Pune 20
Redmond 20
Dallas 17
Brussels 16
Marche 15
Milan 15
Kraków 13
São Paulo 13
Rome 12
Nuremberg 11
Jiaxing 10
Kilburn 10
Izmir 9
Porto 9
Chiswick 8
Fayetteville 8
Nanjing 7
Santa Clara 7
Antwerp 6
Appignano 6
Brooklyn 6
Civitanova Marche 6
Hounslow 6
Jiujiang 6
San Francisco 6
Shenzhen 6
Southwark 6
Tashkent 6
Toronto 6
Vienna 6
Yiwu 6
Boston 5
Casoria 5
Falls Church 5
New Bedfont 5
Pescara 5
Rio de Janeiro 5
Torre Annunziata 5
Warsaw 5
Xi'an 5
Belgrade 4
Chicago 4
Curitiba 4
Dearborn 4
Ho Chi Minh City 4
Lunano 4
Napoli 4
Osasco 4
Perugia 4
Prescot 4
Senigallia 4
Suzhou 4
Wuxi 4
Acton 3
Amsterdam 3
Anápolis 3
Belo Horizonte 3
Bologna 3
Falerone 3
Goiânia 3
Hangzhou 3
Hanover 3
Jinhua 3
Totale 7.706
Nome #
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma 225
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database 192
Prevalence and clinical outcome of hepatic haemangioma with specific reference to the risk of rupture: a large retrospective cross-sectional study. 148
Ageing-related expression of Twinfilin-1 regulates cholangiocyte biological response to injury 124
Acetaldehyde-collagen adducts in N-nitrosodimethylamine-induced liver cirrhosis in rats. 114
A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury 113
Nlrp3 Activation Induces Il-18 Synthesis and Affects the Epithelial Barrier Function in Reactive Cholangiocytes 109
Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals 106
Hepatitis E in a region of Italy: An emerging autochthonous infection? 106
Exendin-4 restores ppar-alpha and ppar-gamma activity in nash and reduces insulin resistance, pro-inflammatory mediators and total fatty acid content 104
HDL cholesterol protects from liver injury in mice with intestinal specific LXRα activation 102
Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury. 101
Predictors of Worse Prognosis in Young and Middle-Aged Adults Hospitalized with COVID-19 Pneumonia: A Multi-Center Italian Study (COVID-UNDER50) 101
Research Strands in Dermatology and Gastroenterology Units of Department of Clinical and Molecular Sciences in Polytechnic Marche University 98
Tocilizumab in COVID-19 interstitial pneumonia 98
Mechanisms for increased risk of diabetes in chronic liver diseases 98
Plasma membrane order parameter in periportal and perivenular hepatocytes isolated from ethanol-treated rats. 98
Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. 97
Collagen-acetaldehyde adducts in alcoholic and nonalcoholic liver diseases. 96
Endoplasmic Reticulum stress induces hepatic stellate cell apoptosis and contributes to fibrosis resolution 96
From the metabolic syndrome to NAFLD or vice versa? 95
Immunological risk factors in biliary strictures after liver transplantation 95
Collagen synthesis by liver stellate cells is released from its normal feedback regulation by acetaldehyde-induced modification of the carboxyl-terminal propeptide of procollagen. 94
Liver transplantation in patients with common variable immunodeficiency: a report of two cases 92
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 92
Leptin enhances cholangiocarcinoma cell growth. 92
Mild impact of SARS-CoV-2 infection on the entire population of liver transplant recipients: the experience of an Italian Centre based in a high-risk area 91
Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. 89
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 89
The Na+/H+ exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells. 88
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 88
Glucagon-like peptide-1receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced bya high-fat diet in nonalcoholic steatohepatitis 88
PDX-1 mRNA expression in endoscopic ultrasound-guided fine needle cytoaspirate: Perspectives in the diagnosis of pancreatic cancer 88
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression from NAFLD to NASH 88
Unusual Site Thrombosis: Focus on Myeloproliferative Neoplasms with Splachnic or Cerebral Venous Thrombosis 88
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 87
Transforming growth factor beta 1 increases the number of apoptotic bodies and decreases intracellular pH in isolated periportal and perivenular rat hepatocytes. 86
Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. 86
Fibrogenic effect of oxidative stress on rat hepatic stellate cells. 86
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions 86
Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice 85
Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. 85
Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. 85
Simultaneous characterization of progenitor cell compartments in adult human liver. 84
Wine: risk factors for liver disease and antifibrotic compounds. 84
Cariporide a selective Na+ /H+ exchange inhibitor, reduces PDGF-induced proliferation and oxidative stress product formation in rat hepatic stellate cells (HSC). 84
Years of life that could be saved from prevention of hepatocellular carcinoma 83
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 83
Early response of alpha2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-beta independent. 82
HCC development is associated to peripheral insulin resistance in a mouse model of NASH 82
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial 82
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study 81
Increased liver localization of lipopolysaccharides in human and experimental non-alcoholic fatty liver disease 81
HIV protein gp120 and chemokines receptor for liver fibrosis. 80
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. 80
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO) 80
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 80
Observer agreement in endoscopic assessment of ulcerative colitis. 79
From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights. 79
Metabolic disorders across hepatocellular carcinoma in Italy 79
Club Drugs: Psychotropic Effects and Psychopathological Characteristics of a Sample of Inpatients 79
Semaphorin 7A contributes to TGF-β-mediated liver fibrogenesis 78
Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease 78
Brivanib in combination with Notch3 silencing shows potent activity in tumour models 78
Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. 76
Fibrogenesis in nonalcoholic steatohepatitis. 76
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 76
Therapy with direct-acting antiviral agents in transplanted patients with HCV recurrence: a retrospective analysis 76
Exendin-4, a glucagon-like protein-1 receptor agonist, reduces proinflammatory conditions, and increases lipid oxidation and insulin sensitivity in hepatocytes from nonalcoholic steatohepatitis rats 75
[L-sulpiride versus metoclopramide in functional dyspepsia: a randomized double-blind study] 75
Regulation of intracellular pH in isolated periportal and perivenular rat hepatocytes. 75
Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation 75
LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease 75
Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. 75
Gut-pancreas-liver axis as a target for treatment of nafld/nash 75
Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. 74
Liver transplantation in neurological Wilson's Disease: is there indication? A case report 74
A "systems medicine" approach to the study of non-alcoholic fatty liver disease 74
COVID-19 in an international European liver transplant recipient cohort 74
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. 73
Inhibition of the NA(+)/H(+) exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. 72
Carrier-mediated transport of conjugated bile acids across the basolateral membrane of biliary epithelial cells. 71
Nonalcoholic fatty liver disease impairs the cytochrome P-450-dependent metabolism of α-tocopherol (vitamin E) 71
A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list 70
Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo. 70
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 70
The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study 70
A 360-degree overview of paediatric NAFLD: Recent insights 69
Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference 69
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 69
Endogenous opioid peptides and chronic liver disease: from bedside to bench. 68
Characterization of ion transport mechanisms regulating intracellular pH in hepatic stellate cells. 68
PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: possible implications for sclerosing cholangitis 67
Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. 67
Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma 67
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. 66
Lipotoxicity and the gut-liver axis in NASH pathogenesis 66
Cell proliferation following extrahepatic biliary obstruction. Evaluation by immunohistochemical methods. 65
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation 65
Effect of cyanidin 3-O-β-glucopyranoside on hepatic stellate cell proliferation and collagen synthesis induced by oxidative stress 65
Totale 8.628
Categoria #
all - tutte 74.127
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.127


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020256 0 0 0 0 0 0 0 0 0 0 58 198
2020/20212.281 147 219 276 52 258 143 207 163 198 225 258 135
2021/20221.316 81 330 39 31 8 52 84 80 80 95 196 240
2022/20232.538 199 257 164 187 154 645 0 132 541 14 177 68
2023/20241.459 239 37 93 272 216 289 23 55 10 44 17 164
2024/20252.531 307 256 122 38 90 186 316 141 601 326 148 0
Totale 12.065